Heron Therapeutics, Inc. (HRTX), a prominent biotechnology company dedicated to enhancing patient lives through therapeutic innovations, has revealed a comprehensive cost reduction plan and corporate restructuring. These significant actions were undertaken following a thorough strategic review of the company's operations by its new management team. The primary goal is to streamline the organization and achieve profitability while maintaining a focus on commercial execution.

‍

The Plan and Management's Vision

The cost reduction plan and restructuring were prompted by an internal review conducted by Heron's new management team, aimed at maximizing the company's potential. Craig Collard, the Chief Executive Officer of Heron, expressed his confidence in these measures as an initial step toward a sustainable future. Although difficult decisions were made, they are seen as necessary to position Heron for long-term success. The company's focus will now be on enhancing product value and operational efficiency, which ultimately benefits its shareholders.

‍

Realigning Resources and Financial Boost

Heron Therapeutics is taking significant steps to align its resources optimally and unlock the full potential of its assets. Alongside the corporate restructuring, the company also completed a concurrent $30 million equity financing. This move is considered vital in realigning resources to enhance Heron's commercial capabilities. With the current operational plan, Heron believes this financing will be the final equity raise needed before achieving cash flow positivity.

‍

The Cost Reduction Plan

Heron's cost reduction plan is centered around streamlining operational expenditures, which includes reducing research and development as well as general and administrative expenses. The company aims to achieve profitability by late 2024. A substantial portion of the expected cash savings will come from cutting external spend through renegotiating and right-sizing key vendor contracts, potentially saving over $31 million through 2025. In line with this plan, Heron has taken the difficult step of reducing its employee base by 25%, a move expected to result in non-recurring cash expenses of around $5.9 million in 2023.

‍

A Focus on Efficiency and Growth

Despite the corporate restructuring and layoffs, Heron Therapeutics remains steadfast in its commitment to optimizing operational expenses in the future. Mr. Collard emphasized the importance of efficient operations, combined with a focus on product optimization and innovative commercial strategies. The company plans to leverage the growth potential of its oncology and acute care portfolios to ensure long-term success and performance.